Cureus
April 1, 2023
Karina Wang, Yiqun Sun, Brenda Nava et al.
14 citations
Background Psilocybin use, along with other psychedelics, has seen an increased interest among professionals in the medical community due to its potential therapeutic benefits for psychiatric disorders, substance use disorders (SUD), and palliative care. While it is certain that more research is necessary as psychedelic-assisted therapy becomes more prevalent, it will most likely be future...
History of the Human Sciences
March 29, 2023
Des O'Rawe
This article explores how post-war documentary film-makers negotiated complex social, formal, and autobiographical issues associated with representing mental illness and its treatments, and the extent to which their respective approaches helped to challenge conventional attitudes to alternative psychotherapies – especially within the context of advances in new documentary film-making...
Psychiatric Services
March 29, 2023
Gregory S. Barber, Charles C. Dike
63 citations
In recent years, psychedelic-assisted psychotherapies have reentered the realm of rigorous scientific inquiry, garnering much attention from both the psychiatric community and the broader public. Headlines on major media platforms frequently tout the psychedelic future of psychiatry, and patients increasingly ask about the prospect of using psychedelics during their sessions. Despite this...
Folia Pharmacologica Japonica
March 28, 2023
Daisuke Ibi
1 citation
Major depressive disorder presents a substantial global health burden, and at least 30-40% of patients exhibit treatment resistance to antidepressants. Ketamine, an NMDA receptor antagonist, is used as an anesthetic agent. In 2019, the U.S. Food and Drug Administration (FDA) approved esketamine (the S-enantiomer of ketamine) as a therapeutic agent for treatment-resistant depression; however,...
Psychiatric News
March 27, 2023
Terri D’arrigo
Back to table of contents Previous article Next article Annual MeetingFull AccessExperts to Discuss the Ethics of PsychedelicsTerri D'ArrigoTerri D'ArrigoPublished Online:27 Mar 2023https://doi.org/10.1176/appi.pn.2023.04.3.10AbstractA session at APA's Annual Meeting will cover the current state of psychedelics research and offer points to consider in the event of broad psychedelics...
Journal of Psychopharmacology
March 20, 2023
Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al.
153 citations
Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature. Methods: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with...
Journal of Psychoactive Drugs
March 18, 2023
Raman Sharma, Rachel Batchelor, Jacqueline Sin
25 citations
Renewed interest in psychedelic substances in the 21st century has seen the exploration of psychedelic treatments for various psychiatric disorders including substance use disorder (SUD). This review aimed to assess the effectiveness of psychedelic treatments for people with SUD and those falling below diagnostic thresholds (i.e. substance misuse). We systematically searched 11 databases, trial...
March 17, 2023
Terence H. W. Ching, Rachael Grazioplene, Christopher Pittenger et al.
6 citations
preprint
The Yale Program for Psychedelic Science (YPPS) supports a multi-disciplinary research community dedicated to investigating the effects of psychedelic substances on brain function, cognition, and behavior, including their therapeutic potential in treating neuropsychiatric conditions. In support of this mission, YPPS is testing the safety and efficacy of psilocybin, administered in conjunction...
Journal of Humanities Arts and Social Science
March 13, 2023
Ruoqi Zhang
Psychedelics are becoming increasingly popular as an entry point into difficult- to-treat psychiatric illnesses and a supplement to existing treatments. However, many people view these substances with caution due to increased incidents where they've been used illegally in unsupervised settings. This paper argues that adding psychedelics to the treatment of mental illness can be beneficial for...
American Journal of Clinical Oncology
March 13, 2023
Dakota Sicignano, Kimberly Snow-Caroti, A. V. Hernandez et al.
Objectives: Life-threatening cancer or other diseases can induce anxiety and depressive symptoms. We performed a systematic review with meta-analyses of randomized controlled trials assessing patients with cancer or other life-threatening diseases using validated anxiety and depression scales. Methods: PubMed was searched up to November 15, 2022 and citations were applied to prespecified...